摘要
目的研究非小细胞肺癌(non-small cell lung cancer,NSCLC)的四种不同化疗方案的药物经济学效果和流行病学临床评价。方法采用回溯法筛选了129例非小细胞肺癌病例,分成4组,分别为I组NP方案(长春瑞滨NVB+顺铂DDP);II组GP(吉西他滨GEM+顺铂DDP);III组NPA方案(长春瑞滨NVB+顺铂DDP+艾迪AIDI);IV组NPK(长春瑞滨NVB+顺铂DDP+薏苡仁提取物(康莱特KLT))。运用药物流行病学的疗效比较和药物经济学的成本-效果分析方法进行研究。结果4组疗效分别为31.43%,36.36%,41.94%,53.33%。不良反应IV和III组低于I和II组。生活质量IV>III>II>I组。成本效果比分别为550.22、556.48、641.43、511.58元。结论NP方案总成本最低但疗效也最低,NPK方案疗效最好,并且每提得一个疗效百分点其花费最小,最具经济学意义。
Aim To analyze the cost-effectiveness and evaluate clinical of pharmacoepidemiology of four combination chemotherapy of NSCLC. Methods 129 patients,who were diagnosed as non-small cell lung cancer,were randomly divided into four treated group. The Ⅰ group is NP which were given NVB and DDP. The II group is GP which were given GEM and DDP. The Ⅲ group is NPA which were given NVB, DDP and AIDI. The Ⅳ group is NPK which were given NVB, DDP and KLT. The four groups were assessed with clinical evaluation of pharmacoepidemiology and cost effectiveness analysis of pharmacoeconomics. Results The clinical effectiveness of the four groups is 31.43% ,36.36% ,41.94% ,53.33% respectively. The adverse events of the Ⅰ and Ⅱ group are more than the Ⅲ and Ⅳ group. The ratio of cost effectiveness in four groups is 550.22,556.48,641.43,511.58 yuan respectively. Conclusions The NP group is the best one in costing least but the effect is the lowest. The NPK group is the best one in clinical effectiveness and cost effectiveness.
出处
《安徽医药》
CAS
2007年第2期174-176,共3页
Anhui Medical and Pharmaceutical Journal
关键词
非小细胞癌
成本效果分析
流行病学
临床评价
non-small cell lung cancer
cost effectiveness analysis
pharmacoepidemiology
clinical evaluation
